Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Tremfya Market Value Growth And Long-Term Outlook
Historical growth in this period was primarily fueled by a rising incidence of psoriasis and psoriatic arthritis, the proven efficacy of biologic therapies, an expansion in specialized dermatology services, enhanced patient compliance with biologics, and more comprehensive reimbursement provisions for biologic medications.
The anticipated growth during the forecast period is primarily fueled by a rising need for continuous management of inflammatory diseases, the extended application of biologics in gastroenterology, and a burgeoning preference for less frequent drug administration regimens. Additionally, increased investment in monoclonal antibody therapies and a stronger emphasis on tailored immunology treatments also contribute to this expansion. Meanwhile, the key trends expected over the forecast period involve the increased adoption of IL-23 inhibitor therapies, a heightened demand for biologic treatments with longer intervals between doses, the broadening of indications for autoimmune diseases, a greater use of subcutaneous biologic injections, and an intensified focus on targeted immunomodulation.
Get A Free Sample Report With In-Depth Market Insights:
Tremfya Market Growth Factors Behind Sustained Expansion
The increasing occurrence of autoimmune conditions is anticipated to boost the Tremfya market in the future. These diseases are characterized by the body’s immune system erroneously attacking its own cells, tissues, or organs, mistaking them for external threats. This surge in autoimmune disease cases stems from factors such as genetic susceptibility, environmental provocations, shifts in lifestyle, greater public awareness, and advancements in diagnostic methods. Tremfya, a monoclonal antibody designed to target interleukin-23 (IL-23), aids in controlling autoimmune disorders by moderating the immune system’s excessive reaction, decreasing inflammation, and easing symptoms in ailments like psoriasis and psoriatic arthritis. For instance, a February 2024 report by Arthritis Australia, an Australia-based non-profit organization, estimates that in 2025, approximately 212,136 males and 362,137 females are expected to suffer from rheumatoid arthritis (RA), with these figures projected to increase by 2040 to roughly 280,040 males and 479,828 females. Consequently, the growing incidence of autoimmune diseases is fueling the expansion of the Tremfya market.
Tremfya Market Segment Analysis: What Are The Core Market Categories?
The tremfya market covered in this report is segmented –
1) By Indication: Moderate-To-Severe Plaque Psoriasis, Active PsA
2) By Formulation: Subcutaneous Injection, Intravenous Infusion
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies
4) By End User: Adult Patients, Geriatric Patients
Tremfya Market Industry Trends Fueling Future Revenue Growth
Leading companies in the Tremfya market are securing regulatory clearances to broaden their treatment applications, including conditions like moderate-to-severe Crohn’s disease, thereby expanding the potential patient population and market reach. These regulatory approvals signify formal permission from bodies such as the Food and Drug Administration (FDA) or European Medicines Agency (EMA), enabling a drug to be sold for particular uses once its safety, effectiveness, and quality have been proven. As an illustration, Johnson & Johnson, a pharmaceutical firm based in the US, obtained FDA approval in September 2024 for TREMFYA (guselkumab) to treat adults experiencing moderately to severely active ulcerative colitis, making it the premier dual-acting interleukin-23 inhibitor sanctioned for this illness. This decision stems from favorable outcomes observed in the Phase 2b/3 QUASAR study, where roughly 50% of participants achieved clinical remission following 44 weeks of therapy. TREMFYA functions by targeting interleukin-23, which aids in stabilizing the inflammatory response within the colon.
Tremfya Market Top Companies Driving Competitive Growth
Major companies operating in the tremfya market are Johnson & Johnson
View The Full Tremfya Market Report:
Tremfya Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the tremfy market in 2025. The regions covered in the tremfya market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
